

VIA FIRST CLASS MAIL

I hereby certify that this correspondence is being deposited with the United States Postal Services as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on December 8, 2000

FULBRIGHT & JAWORSKI L.L.P.

By



LUD 5615 (09905230)

GP 1642
Box seq WD
10/C
RECEIVED
DEC 18 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : JAGER, et al.
Serial No. : 09/451,739
Filed : November 30, 1999
For : ISOLATED NUCLEIC ACID MOLECULES ENCODING
CANCER ASSOCIATED ANTIGENS, THE ANTIGENS
PER SE, AND USES THEREOF
Group Art Unit : 1642
Examiner : G. Nickol

TECH CENTER 1600/2900

RECEIVED

DEC 27 2000

TECH CENTER 1600/2900

December 8, 2000

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231


**LETTER RE
SEQUENCES**

Responsive to the office action of December 1, 2000, a copy of which is attached, please replace the paper copy of sequence information in this case and the computer readable form thereof with the attached. The undersigned hereby declares that, to the best of his knowledge, the information on the submitted paper copy is identical to the information in the computer readable form of sequence information, and both are identical to information presented in the application as filed. No new matter is believed to be presented.

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.

By



Norman D. Hanson
Reg. No. 30,946

666 Fifth Avenue
New York, New York 10103
(212) 318-3000

RECEIVED

DEC 27 2000

TECH CENTER 100



<110> Jager, Dirk
Scanlan, Matthew
Gure, Ali
Jager, Elke
Knuth, Alexander
Old, Lloyd
Chen, Yao-tseng

<120> Isolated Nucleic Acid Molecules Encoding Cancer Associated Antigens,
the Antigens per se, and Uses Thereof

<130> LUD 5615

<140> 09/451,739

<141> 1999-11-30

<160> 19

<210> 1

<211> 1533

<212> DNA

<213> Homo sapiens

<220>

<221> CDS


<222> 235

<400> 1

ggttttccac gttggacaag tgcggctcgg cggccagcgg agcgcgcccc ttcccgtgc 60
ccgctccgct cctctcttct acccagccca gtgggcgagt gggcagcggc ggccgcggcg 120
ctgggccctc tcccgccggt gtgtgcgcgc tgcgtacgcgc ggcccccggc gccagccccg 180
ccgcctgaga gggggcctgc gccgccggcc ggggcgtgcg cccgggagcc accgncaccg 240
cggccccgcgc cctcaggcgc tggggctccc gcggaccggg aggcggcgga cgggctcggc 300
agatgtagcc gccgggccga agcaggagcc ggccgggggg cgccgggaga gcgagggctt 360
tgcattttgc agtgctatct tttgaggggg gcggaggggt gaggaagtcg gaaagccgcg 420
ccgagtcgcc ggggacctcc ggggtgaacc atgttgagtc ctgccaacgg ggagcagctc 480
cacctggtga actatgtgga ggactacctg gactccatcg agtccctgcc ttctgacttg 540
cagagaaatg tctcgtgat gcgggagatc gacgcgaaat accaagagat cctgaaggag 600
ctagacgagt gctacgagcg cttcagtcgc gagacagacg gggcgagaa gcggcggatg 660
ctgcactgtg tgcagcgcgc gctgatccgc agccaggagc tgggcgacga gaagatccag 720
atcgtgagcc agatggtgga gctggtggag aaccgcacgc ggcaggtgga cagccacgtg 780
gagctgttcg aggcgcagca ggagctgggc gacacagcgg gcaacagcgg caaggctggc 840
gcggacaggc ccaaaggcga ggcggcagcg caggctgaca agcccaacag caagcgctca 900
cggcggcagc gcaacaacga gaaccgtgag aacgcgtcca gcaaccacga ccacgacgac 960
ggcgccctcg gcacacccaa ggagaagaag gccaagacct ccaagaagaa gaagcgctcc 1020
aaggccaagg cggagcgaga ggcgtcccct gccgacctcc ccatcgacct caacgaacct 1080
acgtactgtc tgtgcaacca ggtctcctat ggggagatga tcggctgcga caacgacgag 1140
tgcccatcg agtggttcca cttctcgtgc gtggggctca atcataaacc caagggaag 1200

DEC 18 2000

```
<210> 3
<211> 742
<212> DNA
<213> Homo sapiens
<220>
<400> 3
cgccgtccac accccagegg ccctgacgct gtcccttcg cgacctcgc ctctgaaaaa 60
```



RECEIVED

DEC 27 2000

TECH CENTER


agtgcagggc aaggccacgc cccgcgaggg gccggcctcg agcgcgagc ccgagggcc 120
tgggacgaga tcctgaagga gctagacgag tgctacgagc gcttcagtcg cgagacagac 180
ggggcgacga agcggcggat gctgcactgt gtgcagcgcg cgctgatccg cagccaggag 240
ctgggagcag agaagatcca gatcgtgagc cagatggtgg agctggtgga gaaccgcagc 300
cggcaggtgg acagccacgt ggagctgttc gaggcgcagc aggagctggg cgacacagcg 360
ggcaacagcg gcaaggctgg cgcgacaggg cccaaaggcg aggcggcagc gcaggctgac 420
aagcccaaca gcaagcgctc acggcgagcag cgcaacaacg agaaccgtga gaacgcgtcc 480
agcaaccacg accacgacga cggcgccctcg ggcacacca aggagaagaa ggccaagacc 540
tccaagaaga agaagcgctc caaggccaag gcgagcgag aggcgtcccc tgccgacctc 600
cccatcgacc ccaacgaacc cacgtactgt ctgtgcaacc aggtctccta tggggagatg 660
atcggtcgcg acaacgacga gtgccccatc gagtgggtcc acttctcgctg cgtggggctc 720
aatcataaac ccaagggcaa gt 742

<210> 4
<211> 857
<212> DNA
<213> Homo sapiens
<400> 4

cctccgagaa cgggtgtccat ggcacagggc gggaaagat aaggcctagg gaaggcgccc 60
ctcgggccta tccacctctt ctggggctcg gcactaggaa gcagcttccc tctcaggccc 120
ctttgtctcc aagccgttcc aaactgagta ccgggagacg acaaaaaggg agggcggtga 180
cggtatggcg aggcgcggga gccgcctagg ctgctgggag tgggtgtccg gccgcggaat 240
ggagatcctg aaggagctag acgagtgtca cgagcgcttc agtcgcgaga cagacggggc 300
gcagaagcgg cggtatgtgc actgtgtgca gcgcgcgtg atccgcagcc aggagctggg 360
cgacgagaag atccagatcg tgagccagat ggtggagctg gtggagaacc gcacgcggca 420
ggtggacagc cacgtggagc tgttcgaggc gcagcaggag ctgggcgaca cagcgggcaa 480
cagcggcaag gctggcgcg acaggcccaa aggcgagggc gcagcgagc ctgacaagcc 540
caacagcaag cgctcacggc ggcagcgcaa caacgagaac cgtgagaacg cgtccagcaa 600
ccacgaccac gacgacggcg cctcgggcac acccaaggag aagaaggcca agacctcaa 660
gaagaagaag cgctccaagg ccaaggcgga gcgagaggcg tcccctgccc acctcccat 720
cgaccccaac gaaccacgt actgtctgtg caaccaggtc tcctatgggg agatgatcgg 780
ctgcgacaac gacgagtgcc ccatcgagtg gttccacttc tcgtgcgtgg ggctcaatca 840
taaaccgaag ggcaagt 857

<210> 5
<211> 279
<212> PRT
<213> Homo sapiens
<400> 5

Met Leu Ser Pro Ala Asn Gly Glu Gln Leu His Leu Val Asn Tyr Val



RECEIVED

DEC 27 2000

TECH CENTER 1600

RECEIVED

DEC 18 2000

TECH CENTER 1600

1 5 10 15

Glu Asp Tyr Leu Asp Ser Ile Glu Ser Leu Phe Asp Leu Gln Arg
20 25 30

Asn Val Ser Leu Met Arg Glu Ile Asp Ala Lys Tyr Gln Glu Ile Leu
35 40 45

Lys Glu Leu Asp Glu Cys Tyr Glu Arg Phe Ser Arg Glu Thr Asp Gly
50 55 60

Ala Gln Lys Arg Arg Met Leu His Cys Val Gln Arg Ala Leu Ile Arg
65 70 75 80

Ser Gln Glu Leu Gly Asp Glu Lys Ile Gln Ile Val Ser Gln Met Val
85 90 95

Glu Leu Val Glu Asn Arg Thr Arg Gln Val Asp Ser His Val Glu Leu
100 105 110

Phe Glu Ala Gln Gln Glu Leu Gly Asp Thr Val Gly Asn Ser Gly Lys
115 120 125

Val Gly Ala Asp Arg Pro Asn Gly Asp Ala Val Ala Gln Ser Asp Lys
130 135 140

Pro Asn Ser Lys Arg Ser Arg Arg Gln Arg Asn Asn Glu Asn Arg Glu
145 150 155 160

Asn Ala Ser Ser Asn His Asp His Asp Asp Gly Ala Ser Gly Thr Pro
165 170 175

Lys Glu Lys Lys Ala Lys Thr Ser Lys Lys Lys Lys Arg Ser Lys Ala
180 185 190

Lys Ala Glu Arg Glu Ala Ser Pro Ala Asp Leu Pro Ile Asp Pro Asn
195 200 205

Glu Pro Thr Tyr Cys Leu Cys Asn Gln Val Ser Tyr Gly Glu Met Ile
210 215 220

Gly Cys Asp Asn Asp Glu Cys Pro Ile Glu Trp Phe His Phe Ser Cys
225 230 235 240

Val Gly Leu Asn His Lys Pro Lys Gly Lys Trp Tyr Cys Pro Lys Cys
245 250 255

Arg Gly Glu Asn Glu Lys Thr Met Asp Lys Ala Leu Glu Lys Ser Lys
260 265 270

Lys Glu Arg Ala Tyr Asn Arg
275


<210> 6
 <211> 210
 <212> PRT
 <213> Homo sapiens
 <220>
 <400> 6

Met Leu His Cys Val Gln Arg Ala Leu Ile Arg Ser Gln Glu Leu Gly
1 5 10 15

Asp Glu Lys Ile Gln Ile Val Ser Gln Met Val Glu Leu Val Glu Asn
20 25 30

Arg Thr Arg Gln Val Asp Ser His Val Glu Leu Phe Glu Ala Gln Gln

C1
cont



RECEIVED
DEC 27 2000
TECH CENTER 1600/2300

35 40
Glu Leu Gly Asp Thr Val Gly Asn Ser Gly Lys Val Glu Ala Asp Arg
50 55 60
Pro Asn Gly Asp Ala Val Ala Gln Ser Asp Lys Pro Asn Ser Lys Arg
65 70 75 80
Ser Arg Arg Gln Arg Asn Asn Glu Asn Arg Glu Asn Ala Ser Ser Asn
85 90 95
His Asp His Asp Asp Gly Ala Ser Gly Thr Pro Lys Glu Lys Lys Ala
100 105 110
Lys Thr Ser Lys Lys Lys Lys Arg Ser Lys Ala Lys Ala Glu Arg Glu
115 120 125
Ala Ser Pro Ala Asp Leu Pro Ile Asp Pro Asn Glu Pro Thr Tyr Cys
130 135 140
Leu Cys Asn Gln Val Ser Tyr Gly Glu Met Ile Gly Cys Asp Asn Asp
145 150 155 160
Glu Cys Pro Ile Glu Trp Phe His Phe Ser Cys Val Gly Leu Asn His
165 170 175
Lys Pro Lys Gly Lys Trp Tyr Cys Pro Lys Cys Arg Gly Glu Asn Glu
180 185 190
Lys Thr Met Asp Lys Ala Leu Glu Lys Ser Lys Lys Glu Arg Ala Tyr
195 200 205
Asn Arg
210

<210> 7
<211> 235
<212> PRT
<213> Homo sapiens
<400> 7

Met Glu Ile Leu Lys Glu Leu Asp Glu Cys Tyr Glu Arg Phe Ser Arg
1 5 10 15
Glu Thr Asp Gly Ala Gln Lys Arg Arg Met Leu His Cys Val Gln Arg
20 25 30
Ala Leu Ile Arg Ser Gln Glu Leu Gly Asp Glu Lys Ile Gln Ile Val
35 40 45
Ser Gln Met Val Glu Leu Val Glu Asn Arg Thr Arg Gln Val Asp Ser
50 55 60
His Val Glu Leu Phe Glu Ala Gln Gln Glu Leu Gly Asp Thr Val Gly
65 70 75 80
Asn Ser Gly Lys Val Gly Ala Asp Arg Pro Asn Gly Asp Ala Val Ala
85 90 95
Gln Ser Asp Lys Pro Asn Ser Lys Arg Ser Arg Arg Gln Arg Asn Asn
100 105 110
Glu Asn Arg Glu Asn Ala Ser Ser Asn His Asp His Asp Asp Gly Ala
115 120 125
Ser Gly Thr Pro Lys Glu Lys Lys Ala Lys Thr Ser Lys Lys Lys Lys
130 135 140

Arg Ser Lys Ala Lys Ala Glu Arg Glu Ala Ser Pro Ala Asp Leu Pro
145 150 155 160

Ile Asp Pro Asn Glu Pro Thr Tyr Cys Leu Cys Asn Gln Val Ser Tyr
165 170 175

Gly Glu Met Ile Gly Cys Asp Asn Asp Glu Cys Pro Ile Glu Trp Phe
180 185 190

His Phe Ser Cys Val Gly Leu Asn His Lys Pro Lys Gly Lys Trp Tyr
195 200 205

Cys Pro Lys Cys Arg Gly Glu Asn Glu Lys Thr Met Asp Lys Ala Leu
210 215 220

Glu Lys Ser Lys Lys Glu Arg Ala Tyr Asn Arg
225 230 235

<210> 8

<211> 772

<212> DNA

<213> Homo sapiens

<221> CDS

<222> 689,714

<400> 8

aaagcgttct cggcggcagc gcaacaacta gaaccgtgag aacgcgtcca gcaaccgcga 60
cccacgacga cgtcacctcg ggcacgccca aggagaagaa agcccagacc tctaagaaga 120
agcagggctc catggccaag gcgtagcggc aggcgtcccc cgcagacctc cccatcgacc 180
ccagcgagcc ctctactgg gagatgatcc gctgcgacaa cgaatgcccc atcgagtgg 240
tccgcttctc gtgtgtgagt ctcaaccata aaccaaagcg caagtggtag tgttcagat 300
gccggggaaa gaacgatggg caaagccctt gagaagtcca gaaaaaaaac agggcttata 360
acaggtagtt tggggacatg cgtctaatag tgaggagaac aaaataagcc agtgtgttga 420
ttacattgcc acctttgctg aggtgcagga agtgtaaaat gtatatTTTT aaagaatgtt 480
gttagaggcc gggcgcggtg gctcacgcct gtaatcccag cactttggga ggccgaggcg 540
gtcggatcac gaggtcagga gatcgagacc atcctggcta acacggtgaa acccgtctc 600
tactaaaaat tcaaaaaaaa aattagctgg gcgtgggtggc gggcgctgt agtcccagct 660
attcgggagg ctgaggcagg agaatggcnt gaacctggga ggtggagctt gcantgagcc 720
aaggtcgcgc cactgcactc cagcctgggc gacagagcga gactccatct ta 772

<210> 9

<211> 32

<212> DNA

<213> Homo sapiens

<400> 9

cacacaggat ccatgttgag tcttgccaac gg 32

<210> 10

<211> 23

<212> DNA

<213> Homo sapiens

<400> 10

cgtggtcgtg gttgctggac gcg 23



RECEIVED

DEC 18 2000


TECH CENTER 1600

RECEIVED

DEC 27 2000

TECH CENTER 1600

C
Cox
<210> 11
<211> 21
<212> DNA
<213> Homo sapiens
<400> 11
cccagcggcc ctgacgctgt t 21



RECEIVED

DEC 27 2000

TECH CENTER 1600

<210> 12
<211> 23
<212> DNA
<213> Homo sapiens
<400> 12
cgtggctcgtg gttgctggac gcg 23

RECEIVED

DEC 18 2000

TECH CENTER 1600

<210> 13
<211> 23
<212> DNA
<213> Homo sapiens
<400> 13
ggaagagata aggcctaggg aag 23

<210> 14
<211> 23
<212> DNA
<213> Homo sapiens
<400> 14
cgtggctcgtg gttgctggac gcg 23

<210> 15
<211> 2030
<212> DNA
<213> Homo sapiens
<221> CDS
<222> 1628, 1752, 1758, 1769, 1789, 1873, 1908, 1915, 1933, 1970, 1976, 2022
<400> 15
ctcgtgccgt taaagatggt cttctgaagg ctaactgcgg aatgaaagt tctattccaa 60
ctaaagcctt agaattgatg gacatgcaaa ctttcaaagc agagcctccc gagaagccat 120
ctgccttcga gcctgccatt gaaatgcaaa agtctgttcc aaataaagcc ttggaattga 180
agaatgaaca aacattgaga gcagatgaga tactcccatc agaatccaaa caaaaggact 240
atgaagaaag ttcttgggat tctgagagtc tctgtgagac tgtttcacag aaggatgtgt 300
gtttacccaa ggctacacat caaaaagaaa tagataaaat aaatggaaaa ttagaagagt 360
ctcctgataa tgatggtttt ctgaaggctc cctgcagaat gaaagtttct attccaacta 420
aagccttaga attgatggac atgcaaaact tcaaagcaga gcctcccgag aagccatctg 480
ccttcgagcc tgccattgaa atgcaaaaagt ctgttccaaa taaagccttg gaattgaaga 540
atgaacaaac attgagagca gatcagatgt tcccttcaga atcaaaacaa aagaaggttg 600
aagaaaattc ttgggattct gagagtctcc gtgagactgt ttcacagaag gatgtgtgtg 660
taccgaaggc tacacatcaa aaagaaatgg ataaaataag tggaaaatta gaagattcaa 720
ctagcctatc aaaaatcttg gatacagttc attcttgtga aagagcaagg gaacttcaaa 780
aagatcactg tgaacaacgt acaggaaaaa tggaacaaat gaaaaagaag ttttgtgtac 840



RECEIVED

DEC 27 2000

TECH CENTER

tgaaaaagaa actgtcagaa gcaaaagaaa taaaatcaca gtaaaagaa caaaaagtta 900
aatgggaaca agagctctgc agtgtgagat tgactttaaa ccaagaagaa gagaagagaa 960
gaaatgccga tatattaaat gaaaaaatta gggaagaatt aggaagaatc gaagagcagc 1020
ataggaaaga gttagaagtg aaacaacaac ttgaacaggc ttcagaata caagatatag 1080
aattgaagag tgtagaaagt aatttgaatc aggtttctca cactcatgaa aatgaaaatt 1140
atctcttaca tgaaaattgc atgttgaaaa aggaaattgc catgctaaaa ctggaaatag 1200
ccacactgaa acaccaatac caggaaaagg aaaataaata ctttgaggac attaagattt 1260
taaaagaaaa gaatgctgaa cttcagatga ccctaaaact gaaagaggaa tcattaacta 1320
aaagggcatc tcaatatagt gggcagctta aagttctgat agctgagaac acaatgctca 1380
cttctaaatt gaaggaaaaa caagacaaag aaatactaga ggcagaaatt gaatcacacc 1440
atcctagact ggcttctgct gtacaagacc atgatcaaat tgtgacatca agaaaaagtc 1500
aagaacctgc tttccacatt gcaggagatg cttgtttgca aagaaaaatg aatgttgatg 1560
tgagtagtac cgatatataa caatgagggtg ctccatcaac cactttctga agctcaaagg 1620
aaatccanaa gcctaaaaat taatctcaat tatgcaggag atgctctaag agaaaatata 1680
ttggtttcag gaacatgcac aaagagacca acgtgaaaca cagtgtcaaa tgaaggaagc 1740
tgaacacatg tntcaaancg aacaagatna tgtgaacaaa cacttganc agcaggagtc 1800
tctagatcag aaattatttc aactacaaag caaaaatatg tggcttcaac agcaattagt 1860
tcatgcacat aangaaagct gacaacaaaa gcaagataac aattgatntt cattntcttg 1920
agaggaaaaat gcncatcatc ttctaaaaga gaaaaatgag gagatatttn attacnataa 1980
ccatttaaaa aacccgtata tttcaatatg gaaaaaaaaa anaaaaaaaaa 2030

<210> 16

<211> 513

<212> PRT

<213> Homo sapiens

<400> 16

Met Lys Val Ser Ile Pro Thr Lys Ala Leu Glu Leu Met Asp Met Gln
1 5 10 15

Thr Phe Lys Ala Glu Pro Pro Glu Lys Pro Ser Ala Phe Glu Pro Ala
20 25 30

Ile Glu Met Gln Lys Ser Val Pro Asn Lys Ala Leu Glu Leu Lys Asn
35 40 45


Glu Gln Thr Leu Arg Ala Asp Glu Ile Leu Pro Ser Glu Ser Lys Gln
50 55 60

Lys Asp Tyr Glu Glu Ser Ser Trp Asp Ser Glu Ser Leu Cys Glu Thr
65 70 75 80

Val Ser Gln Lys Asp Val Cys Leu Pro Lys Ala Thr His Gln Lys Glu
85 90 95

Ile Asp Lys Ile Asn Gly Lys Leu Glu Glu Ser Pro Asp Asn Asp Gly
100 105 110

C1
cont




RECEIVED
DEC 27 2000
TECH CENTER 1600

Phe Leu Lys Ala Pro Cys Arg Met Lys Val Ser Ile Pro Thr Lys Ala
115 120
Leu Glu Leu Met Asp Met Gln Thr Phe Lys Ala Glu Pro Pro Glu Lys
130 135 140
Pro Ser Ala Phe Glu Pro Ala Ile Glu Met Gln Lys Ser Val Pro Asn
145 150 155 160
Lys Ala Leu Glu Leu Lys Asn Glu Gln Thr Leu Arg Ala Asp Gln Met
165 170 175
Phe Pro Ser Glu Ser Lys Gln Lys Lys Val Glu Glu Asn Ser Trp Asp
180 185 190
Ser Glu Ser Leu Arg Glu Thr Val Ser Gln Lys Asp Val Cys Val Pro
195 200 205
Lys Ala Thr His Gln Lys Glu Met Asp Lys Ile Ser Gly Lys Leu Glu
210 215 220
Asp Ser Thr Ser Leu Ser Lys Ile Leu Asp Thr Val His Ser Cys Glu
225 230 235 240
Arg Ala Arg Glu Leu Gln Lys Asp His Cys Glu Gln Arg Thr Gly Lys
245 250 255
Met Glu Gln Met Lys Lys Lys Phe Cys Val Leu Lys Lys Lys Leu Ser
260 265 270
Glu Ala Lys Glu Ile Lys Ser Gln Leu Glu Asn Gln Lys Val Lys Trp
275 280 285
Glu Gln Glu Leu Cys Ser Val Arg Leu Thr Leu Asn Gln Glu Glu Glu
290 295 300 305
Lys Arg Arg Asn Ala Asp Ile Leu Asn Glu Lys Ile Arg Glu Glu Leu
310 315 320
Gly Arg Ile Glu Glu Gln His Arg Lys Glu Leu Glu Val Lys Gln Gln
325 330 335
Leu Glu Gln Ala Leu Arg Ile Gln Asp Ile Glu Leu Lys Ser Val Glu
340 345 350
Ser Asn Leu Asn Gln Val Ser His Thr His Glu Asn Glu Asn Tyr Leu
355 360 365
Leu His Glu Asn Cys Met Leu Lys Lys Glu Ile Ala Met Leu Lys Leu
370 375 380 385
Glu Ile Ala Thr Leu Lys His Gln Tyr Gln Glu Lys Glu Asn Lys Tyr
390 395 400
Phe Glu Asp Ile Lys Ile Leu Lys Glu Lys Asn Ala Glu Leu Gln Met
405 410 415
Thr Leu Lys Leu Lys Glu Glu Ser Leu Thr Lys Arg Ala Ser Gln Tyr
420 425 430
Ser Gly Gln Leu Lys Val Leu Ile Ala Glu Asn Thr Met Leu Thr Ser
435 440 445
Lys Leu Lys Glu Lys Gln Asp Lys Glu Ile Leu Glu Ala Glu Ile Glu
450 455 460 465
Ser His His Pro Arg Leu Ala Ser Ala Val Gln Asp His Asp Gln Ile

RECEIVED
DEC 18 2000
TECH CENTER 1600

C
OK



RECEIVED

DEC 27 2001

TECH CENTER 1600/2400

470

475

480

Val Thr Ser Arg Lys Ser Gln Glu Pro Ala Phe His Ile Ala Gly Asp
485 490 495

Ala Cys Leu Gln Arg Lys Met Asn Val Asp Val Ser Ser Thr Asp Ile
500 505 510

<210> 17

<211> 33

<212> DNA

<213> Homo sapiens

<400> 17

cacacaggat ccattgcaggc cccgcacaag gag 33

<210> 18

<211> 34

<212> DNA

<213> Homo sapiens

<400> 18

cacacaaagc ttctaggatt tggcacagcc agag 34

<210> 19

<211> 294

<212> PRT

<213> Homo sapiens

<400> 19

Met Pro Leu Cys Thr Ala Thr Arg Ile Pro Arg Tyr Ser Ser Ser Ser
1 5 10 15

Asp Pro Gly Pro Val Ala Arg Gly Arg Gly Cys Ser Ser Asp Arg Leu
20 25 30

Pro Arg Pro Ala Gly Pro Ala Arg Arg Gln Phe Gln Ala Ala Ser Leu
35 40 45

Leu Thr Arg Gly Trp Gly Arg Ala Trp Pro Trp Lys Gln Ile Leu Lys
50 55 60

Glu Leu Asp Glu Cys Tyr Glu Arg Phe Ser Arg Glu Thr Asp Gly Ala
65 70 75 80

Gln Lys Arg Arg Met Leu His Cys Val Gln Arg Ala Leu Ile Arg Ser
85 90 95

Gln Glu Leu Gly Asp Glu Lys Ile Gln Ile Val Ser Gln Met Val Glu
100 105 110

Leu Val Glu Asn Arg Thr Arg Gln Val Asp Ser His Val Glu Leu Phe
115 120 125

Glu Ala Gln Gln Glu Leu Gly Asp Thr Val Gly Asn Ser Gly Lys Val
130 135 140

Gly Ala Asp Arg Pro Asn Gly Asp Ala Val Ala Gln Ser Asp Lys Pro
145 150 155 160

Asn Ser Lys Arg Ser Arg Arg Gln Arg Asn Asn Glu Asn Arg Glu Asn
165 170 175

Ala Ser Ser Asn His Asp His Asp Asp Gly Ala Ser Gly Thr Pro Lys
180 185 190

Glu Lys Lys Ala Lys Thr Ser Lys Lys Lys Lys Arg Ser Lys Ala Lys



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

09/451.735 11/30/99

JAGER

LUD-5615

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

024972 HM12/1201
FULBRIGHT & JAWORSKI, LLP
655 FIFTH AVE
NEW YORK NY 10103-0198

NICKOL, G

EXAMINER

1642

ART UNIT

PAPER NUMBER

9

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

FULBRIGHT & JAWORSKI, LLP
NEW YORK DOCKETING

Docketed ☒ Not Required ☐

Previously ☐ Updated ☐

Docket No: LUD 5615-102

Action: Sequence listing

Reminder: 12-25-2000

Date: Due/Done 1-7-2001

Initials: [Signature]



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/451739			

RECEIVED

DEC 27 2000

TECH CENTER 1600-2900

EXAMINER	
ART UNIT	PAPER NUMBER

DATE MAILED:


Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Any inquiry concerning this communication should be directed to Examiner **Gary Nickol, Ph.D.**, Art Unit 1642, whose telephone number is **703-305-7143**.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.


SUSAN LINBAR, PH.D
PRIMARY EXAMINER



Application No. **09/451739**

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

RECEIVED

DEC 27 2000

TECH CENTER 100/200

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200



To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

Nichols

RAW SEQUENCE LISTING ERROR REPORT

BIOTECHNOLOGY
SYSTEMS
BRANCH



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:

09/451,739A

Source:

1642

Date Processed by STIC:

7/12/2000

DEC 18 2000

TECH CENTER 1600/2900

RECEIVED

JUL 28 2000

TECH CENTER 1600/2900

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY
EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR FURTHER INFORMATION, PLEASE TELEPHONE MARK SPENCER,
703-308-4212.

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER
VERSION 3.0 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND
TRADEMARK OFFICE WEBSITE. SEE BELOW:

Checker Version 3.0

The Checker Version 3.0 application is a state-of-the-art Windows based software program employing a logical and intuitive user-interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated for the original version of 37 CFR §§1.821 - 1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (WIPO) Standard ST.25.

Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2K-compliant. Checker allows public users to check sequence listings in Computer Readable form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO). Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

Checker Version 3.0 can be down loaded from the USPTO website at the following address:

<http://www.uspto.gov/web/offices/pac/checker>

1642

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/451,739A

DATE: 07/12/2000

TIME: 15:56:26

Input Set : A:\lud-5615.txt

Output Set: N:\CRF3\07122000\I451739A.raw

1 <110> APPLICANT: Jager, Dirk
 2 Scanlan, Matthew
 3 Gure, Ali
 4 Jager, Elke
 5 Knuth, Alexander
 6 Old, Lloyd
 7 Chen, Yao-tseng
 9 <120> TITLE OF INVENTION: Isolated Nucleic Acid Molecules Encoding Cancer Associated Antigens,
 10 the Antigens per se, and Uses Thereof
 12 <130> FILE REFERENCE: LUD 5615
 14 <140> CURRENT APPLICATION NUMBER: 09/451,739A
 16 <141> CURRENT FILING DATE: 1999-11-30
 18 <160> NUMBER OF SEQ ID NOS: 19

Does Not Comply
 Corrected Diskette Needed


ERRORED SEQUENCES

527 <210> SEQ ID NO: 16
 528 <211> LENGTH: 528
 529 <212> TYPE: PRT
 530 <213> ORGANISM: Homo sapiens
 531 <220> FEATURE:
 532 <400> SEQUENCE: 16
 533 Met Lys Val Ser Ile Pro Thr Lys Ala Leu Glu Leu Met Asp Met Gln
 534 1 5 10 15
 536 Thr Phe Lys Ala Glu Pro Pro Glu Lys Pro Ser Ala Phe Glu Pro Ala
 537 20 25 30
 539 Ile Glu Met Gln Lys Ser Val Pro Asn Lys Ala Leu Glu Leu Lys Asn
 540 35 40 45
 542 Glu Gln Thr Leu Arg Ala Asp Glu Ile Leu Pro Ser Glu Ser Lys Gln
 543 50 55 60
 545 Lys Asp Tyr Glu Glu Ser Ser Trp Asp Ser Glu Ser Leu Cys Glu Thr
 546 65 70 75 80
 548 Val Ser Gln Lys Asp Val Cys Leu Pro Lys Ala Thr His Gln Lys Glu
 549 85 90 95
 551 Ile Asp Lys Ile Asn Gly Lys Leu Glu Glu Ser Pro Asp Asn Asp Gly
 552 100 105 110
 554 Phe Leu Lys Ala Pro Cys Arg Met Lys Val Ser Ile Pro Thr Lys Ala
 555 115 120 125
 557 Leu Glu Leu Met Asp Met Gln Thr Phe Lys Ala Glu Pro Pro Glu Lys
 558 130 135 140
 560 Pro Ser Ala Phe Glu Pro Ala Ile Glu Met Gln Lys Ser Val Pro Asn
 561 145 150 155 160
 563 Lys Ala Leu Glu Leu Lys Asn Glu Gln Thr Leu Arg Ala Asp Gln Met
 564 165 170 175
 566 Phe Pro Ser Glu Ser Lys Gln Lys Lys Val Glu Glu Asn Ser Trp Asp
 567 180 185 190

RECEIVED

JUL 28 2000

TECH CENTER 1600/2900



RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/451,739A DATE: 7/12/2000 TIME: 15:56:26

Input Set : A:\lud-5615.txt

Output Set: N:\CRF3\07122000\I451739A.raw

RECEIVED

DEC 27 2000

TECH CENTER 1600/2500

569 Ser Glu Ser Leu Arg Glu Thr Val Ser Gln Lys Asp Val Cys Val Pro
 570 195 200 205
 572 Lys Ala Thr His Gln Lys Glu Met Asp Lys Ile Ser Gly Lys Leu Glu
 573 210 215 220
 575 Asp Ser Thr Ser Leu Ser Lys Ile Leu Asp Thr Val His Ser Cys Glu
 576 225 230 235
 578 Arg Ala Arg Glu Leu Gln Lys Asp His Cys Glu Gln Arg Thr Gly Lys
 E--> 579 260 245 265 250 270 255
 581 Met Glu Gln Met Lys Lys Lys Phe Cys Val Leu Lys Lys Lys Leu Ser
 E--> 582 275 260 280 265 285 270
 584 Glu Ala Lys Glu Ile Lys Ser Gln Leu Glu Asn Gln Lys Val Lys Trp
 E--> 585 290 275 295 280 300 285
 587 Glu Gln Glu Leu Cys Ser Val Arg Leu Thr Leu Asn Gln Glu Glu Glu
 E--> 588 305 310 315 320
 590 Lys Arg Arg Asn Ala Asp Ile Leu Asn Glu Lys Ile Arg Glu Glu Leu
 E--> 591 325 330 335
 593 Gly Arg Ile Glu Glu Gln His Arg Lys Glu Leu Glu Val Lys Gln Gln
 E--> 594 340 345 350
 596 Leu Glu Gln Ala Leu Arg Ile Gln Asp Ile Glu Leu Lys Ser Val Glu
 E--> 597 355 360 365
 599 Ser Asn Leu Asn Gln Val Ser His Thr His Glu Asn Glu Asn Tyr Leu
 E--> 600 370 375 380
 602 Leu His Glu Asn Cys Met Leu Lys Lys Glu Ile Ala Met Leu Lys Leu
 E--> 603 385 390 395 400
 605 Glu Ile Ala Thr Leu Lys His Gln Tyr Gln Glu Lys Glu Asn Lys Tyr
 E--> 606 405 410 415
 608 Phe Glu Asp Ile Lys Ile Leu Lys Glu Lys Asn Ala Glu Leu Gln Met
 E--> 609 420 425 430
 611 Thr Leu Lys Leu Lys Glu Glu Ser Leu Thr Lys Arg Ala Ser Gln Tyr
 E--> 612 435 440 445
 614 Ser Gly Gln Leu Lys Val Leu Ile Ala Glu Asn Thr Met Leu Thr Ser
 E--> 615 450 455 460
 617 Lys Leu Lys Glu Lys Gln Asp Lys Glu Ile Leu Glu Ala Glu Ile Glu
 E--> 618 465 470 475 480
 620 Ser His His Pro Arg Leu Ala Ser Ala Val Gln Asp His Asp Gln Ile
 E--> 621 485 490 495
 623 Val Thr Ser Arg Lys Ser Gln Glu Pro Ala Phe His Ile Ala Gly Asp
 E--> 624 500 505 510
 626 Ala Cys Leu Gln Arg Lys Met Asn Val Asp Val Ser Ser Thr Asp Ile
 E--> 627 515 520 525


numbers JJ

J

FBI

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.



VERIFICATION SUMMARY

 PATENT APPLICATION: US/09/451,739
 DATE: 07/12/2000
 TIME: 15:56:27

Input Set : A:\lud-5615.txt


Output Set: N:\CRF3\07122000\I451739A.raw

L:25 M:283 W: Missing Blank Line separator, <220> field identifier
 L:28 M:283 W: Missing Blank Line separator, <400> field identifier
 L:35 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:1
 L:35 M:340 W: (46) "n" or "Xaa" used: Feature required, for SEQ ID#:1
 L:86 M:283 W: Missing Blank Line separator, <220> field identifier
 L:87 M:283 W: Missing Blank Line separator, <400> field identifier
 L:133 M:283 W: Missing Blank Line separator, <220> field identifier
 L:134 M:283 W: Missing Blank Line separator, <400> field identifier
 L:166 M:283 W: Missing Blank Line separator, <220> field identifier
 L:167 M:283 W: Missing Blank Line separator, <400> field identifier
 L:203 M:283 W: Missing Blank Line separator, <220> field identifier
 L:204 M:283 W: Missing Blank Line separator, <400> field identifier
 L:264 M:283 W: Missing Blank Line separator, <220> field identifier
 L:265 M:283 W: Missing Blank Line separator, <400> field identifier
 L:313 M:283 W: Missing Blank Line separator, <220> field identifier
 L:314 M:283 W: Missing Blank Line separator, <400> field identifier
 L:365 M:283 W: Missing Blank Line separator, <220> field identifier
 L:368 M:283 W: Missing Blank Line separator, <400> field identifier
 L:391 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:8
 L:391 M:340 W: (46) "n" or "Xaa" used: Feature required, for SEQ ID#:8
 L:400 M:283 W: Missing Blank Line separator, <220> field identifier
 L:401 M:283 W: Missing Blank Line separator, <400> field identifier
 L:409 M:283 W: Missing Blank Line separator, <220> field identifier
 L:410 M:283 W: Missing Blank Line separator, <400> field identifier
 L:418 M:283 W: Missing Blank Line separator, <220> field identifier
 L:419 M:283 W: Missing Blank Line separator, <400> field identifier
 L:427 M:283 W: Missing Blank Line separator, <220> field identifier
 L:428 M:283 W: Missing Blank Line separator, <400> field identifier
 L:436 M:283 W: Missing Blank Line separator, <220> field identifier
 L:437 M:283 W: Missing Blank Line separator, <400> field identifier
 L:445 M:283 W: Missing Blank Line separator, <220> field identifier
 L:446 M:283 W: Missing Blank Line separator, <400> field identifier
 L:454 M:283 W: Missing Blank Line separator, <220> field identifier
 L:457 M:283 W: Missing Blank Line separator, <400> field identifier
 L:512 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:15
 L:512 M:340 W: (46) "n" or "Xaa" used: Feature required, for SEQ ID#:15
 L:516 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:15
 L:516 M:340 W: (46) "n" or "Xaa" used: Feature required, for SEQ ID#:15
 L:520 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:15
 L:520 M:340 W: (46) "n" or "Xaa" used: Feature required, for SEQ ID#:15
 L:522 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:15
 L:522 M:340 W: (46) "n" or "Xaa" used: Feature required, for SEQ ID#:15
 L:524 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:15
 L:524 M:340 W: (46) "n" or "Xaa" used: Feature required, for SEQ ID#:15
 L:531 M:283 W: Missing Blank Line separator, <220> field identifier
 L:532 M:283 W: Missing Blank Line separator, <400> field identifier
 L:579 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:16
 L:582 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:16

RECEIVED

JUL 28 2000

TECH CENTER 1600/2900



VERIFICATION SUMMARY

PATENT APPLICATION: US/09/451,739A

DATE: 07/12/2000

TIME: 15:56:27

Input Set : A:\lud-5615.txt

Output Set: N:\CRF3\07122000\I451739A.raw

RECEIVED

DEC 27 2000

TECH CENTER 1000/2500

L:585 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:16
L:588 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:16
L:591 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:16
L:594 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:16
L:597 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:16
L:600 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:16
L:603 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:16
L:606 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:16
L:609 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:16
L:612 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:16
L:615 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:16
L:618 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:16
L:621 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:16
L:624 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:16
L:627 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:16
L:627 M:252 E: No. of Seq. differs, <211>LENGTH:Input:528 Found:512 SEQ:16
L:634 M:283 W: Missing Blank Line separator, <220> field identifier
L:635 M:283 W: Missing Blank Line separator, <400> field identifier
L:643 M:283 W: Missing Blank Line separator, <220> field identifier
L:644 M:283 W: Missing Blank Line separator, <400> field identifier
L:652 M:283 W: Missing Blank Line separator, <220> field identifier
L:653 M:283 W: Missing Blank Line separator, <400> field identifier